© 1997 American Heart Association, Inc.
Articles |
Hemostatic Factors as Predictors of Ischemic Heart Disease and Stroke in the Edinburgh Artery Study
From the Wolfson Unit for Prevention of Peripheral Vascular Diseases, Department of Public Health Sciences, University of Edinburgh, Medical School, Edinburgh, Scotland (F.B.S., A.J.L., F.G.R.F., J.F.P), and the Haemostasis, Thrombosis and Vascular Medicine Unit, University Department of Medicine, Glasgow Royal Infirmary, Glasgow, Scotland (A.R., G.D.O.L.).
Correspondence to Felicity B. Smith, Wolfson Unit for Prevention of Peripheral Vascular Diseases, Department of Public Health Sciences, University of Edinburgh, Medical School, Teviot Place, Edinburgh EH8 9AG, Scotland, UK.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract Plasma fibrinogen is a consistent predictor of ischemic heart disease (IHD) in prospective studies, but there are fewer data relating other hemostatic variables to IHD and also to stroke. We therefore studied the relationships of plasma fibrinogen, von Willebrand factor antigen, tissue plasminogen activator (TPA) antigen, factor VII, and fibrin D-dimer to incidence of IHD and stroke and determined whether any associations could be explained by conventional risk factors and baseline heart disease. In the Edinburgh Artery study, 1592 men and women aged 55 to 74 years, randomly sampled from the general population, were followed prospectively over 5 years to detect fatal and nonfatal IHD and stroke events. During the 5 years, 268 new vascular events were identified. Baseline plasma fibrinogen was independently related to risk of stroke in multivariate analysis that adjusted for cigarette smoking, LDL-cholesterol, systolic blood pressure, and preexisting IHD (relative risk [RR] 1.52, 95% confidence interval [CI] 1.17,1.98). TPA antigen, and fibrin D-dimer were also independently associated with risk of stroke (RR 1.69, 95% CI 1.22,2.35 and RR 1.96, 95% CI 1.12,3.41, respectively). Significant relationships were found between TPA antigen and myocardial infarction (P
.05). In older men and women, increased coagulation
activity and disturbed fibrinolysis are predictors of
future vascular events (both IHD and stroke).
Key Words: tissue plasminogen activator • fibrin D-dimer • ischemic heart disease • stroke
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In seven longitudinal cohort studies, elevated plasma fibrinogen has been shown to be a strong predictor of IHD and stroke independently of the main cardiovascular risk factors.1–7 Impaired fibrinolytic function may also be important in increasing the risk of thrombotic vascular events. Elevated TPA antigen levels were associated with an increased risk of coronary events in patients with angina pectoris or previous myocardial infarction.8–10 Also, TPA antigen was shown to predict future myocardial infarction, although this relationship was not independent of other risk factors.11 There are few data, however, on hemostatic factors such as vWF, factor VII, and fibrin D-dimer1,6 and the incidence of IHD in the general population. Also, few hemostatic factors, with the exception of fibrinogen3,5 and TPA antigen,12 have been examined prospectively in relation to the risk of stroke.
In the cross-sectional phase of the Edinburgh Artery Study, we reported that fibrinogen was associated with IHD.13 In this prospective phase, our aim was to determine whether baseline levels of a range of hemostatic factors were related to increased risks of future IHD and stroke events and whether these associations could be explained by interactions with conventional risk factors or baseline evidence of IHD. We have already reported the relationships of baseline rheologic factors to future IHD and stroke.14
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
The Edinburgh Artery Study is a population-based cohort study comprising a baseline survey and follow-up period of 5 years. A total of 1592 men and women aged 55 to 74 years were initially recruited into the study during 1988. They were selected by age- and sex-stratified random sampling from 11 general practices distributed widely throughout the city to ensure that the catchment population was socioeconomically diverse. The response rate was 65% and follow-up of a 20% sample of nonparticipants showed no significant differences in medical history of heart attack, angina, and peripheral arterial disease compared with participants. Details of the study procedures have been described previously.15
Sample Size
The sample size in the original baseline survey was estimated on
the basis of the number required to conduct a subsequent follow-up
study with adequate power to detect differences in the incidence of
vascular events. Power calculations were performed at the beginning of
the study for plasma fibrinogen, total cholesterol, and
diastolic blood pressure. For example, with 1500 subjects,
a difference of 0.23 g/L in plasma fibrinogen could be detected
with 95% power and the 5% significance level.
Baseline Examination
Subjects attended a university clinic where they completed a
questionnaire that included validated questions on medical history,
angina, intermittent claudication, smoking history, and current
medication. Systolic and diastolic (phase V) blood
pressure values were measured in the right arm after 10 minutes of rest
using a Hawksley random zero sphygmomanometer. A 12-lead ECG was also
recorded using the Minnesota coding system,16
by two independent observers. A 20-mL fasting blood sample was taken
for analysis of hemostatic factors and serum lipids. All
samples were taken between 9 AM and 11 AM to
minimize the effect of diurnal variation on hemostatic factor
levels.
In the laboratory, serum total cholesterol, HDL-cholesterol, and serum triglyceride levels were estimated by a Cobas Bioanalyzer (Roche Products) using standard kits. Fibrinogen was measured in citrated plasma by a thrombin-clotting turbidometric method in a centrifugal analyzer.17 Fibrin D-dimer was measured using a commercial enzyme-linked immunosorbent assay supplied by AGEN. vWF was also estimated using an enzyme-linked immunosorbent assay (DAKO), as was TPA antigen (Biopool). Factor VII activity was measured using a chromogenic assay (Kabi Diagnostica).
Five Year Follow-up
Subjects were followed-up over 5 years to determine the
incidence of fatal and nonfatal cardiovascular events.
Notification of deaths was supplied by the United Kingdom National
Health Service Central Registry. Information on nonfatal events was
obtained from general practitioners, hospital registers,
the Information and Statistics Division of the Scottish Home and Health
Department, and annual questionnaires to the study participants.
Confirmation of all reported cardiovascular events was
sought from hospital or general practitioner records.
In addition, subjects had a 5-year follow-up clinical examination
during 1993 and 1994 during which they completed a self-administered
questionnaire that included questions on smoking and new
cardiovascular events and the World Health Organization
angina and claudication questionnaires.18
Definition of Cardiovascular Events
Criteria used to define MI and stroke were adapted from the
American Heart Association.19 These are described
in detail elsewhere.20 Four categories of disease
were defined: angina pectoris, combined fatal and nonfatal MI, combined
fatal and nonfatal stroke, and a total vascular event group (angina,
MI, and stroke). Transient ischemic attack events were not
included in the stroke category. Multiple events of the same type in a
subject were recorded only once.
Statistical Analysis
Data were analyzed on the University of Edinburgh
mainframe computer using SPSS-X and SAS statistical packages. A
2 test and Student's t test were
used to assess the significance of differences in the sex distribution
and mean levels of conventional risk factors across each of the four
event groups (angina pectoris, MI, stroke, and total vascular events)
relative to those with no evidence of IHD or stroke at baseline. The
Kolmogorov-Smirnov test was used to examine differences in the
distribution of each hemostatic factor across the four categories of
disease relative to the apparently healthy group. For subsequent
analysis, due to positive skewness, square-root transformations
were carried out on the values of TPA, vWF, and factor VII. Fibrin
D-dimer levels were logarithmically transformed because the
distribution was highly skewed. Cigarette smoking was calculated as
packyears (number of years of smoking multiplied by the average number
of packs smoked per day). The distribution of packyears was skewed with
a few heavy smokers and so a square-root transformation was used.
LDL-cholesterol was calculated from the formula:
 |
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Of the original 1592 subjects, 1156 attended for the follow-up examination, a further 131 subjects completed a questionnaire only, and there were 203 deaths. The remaining 102 subjects comprised those who were too ill to attend or did not want to take part in the follow-up examination or who could not be traced. However, during the 5-year follow-up, information was available for the majority of these 102 from annual questionnaires, general practitioners, hospital notes, or death certificates. A total of 1174 subjects had no evidence of angina, MI, or stroke at baseline or during follow-up. A total of 268 subjects with a fatal or nonfatal vascular event was identified. Of these, 92 subjects developed new angina, 166 had a MI, and 45 had a stroke, with several subjects (35) having more than one type of event. The remaining 150 subjects either died of a nonvascular cause or had incomplete data for the study criteria used to define cardiovascular status.
Table 1
shows differences in age and sex
distribution and mean risk factor levels of subjects within the
different categories of vascular events. Subjects who had a stroke or
MI were significantly older (stroke mean 68.3 years, MI mean 66.5
years) than those who had no cardiovascular event
(P.001) and were more likely to be male. Mean
systolic blood pressure was higher in all event categories
compared with those having no event, even although a considerable
proportion of subjects were taking antihypertensive medication: angina
(20.7%), MI (21.1%), stroke (37.8%), total events (26.6%), and no
events (8.9%). In contrast, only 4 subjects in each of the MI and
stroke categories reported taking aspirin or warfarin on a regular
basis. Lifetime smoking (packyear) levels were higher in all the
disease groups and particularly in the stroke category. The proportion
of subjects who had evidence of IHD at baseline varied from 3.3% in
the angina group up to 30.1% in the MI group. By definition, the
angina group was composed of those with no angina at baseline and first
onset during follow-up, thus accounting for the angina group's low
prevalence of IHD at baseline.
|
Median levels and interquartile ranges of hemostatic factors across the
categories of events are shown in Table 2. Baseline levels of all the factors
except factor VII were highest in those who subsequently developed
stroke. Factor VII levels were most elevated in the new angina group
compared with the level in other disease categories. The levels of the
hemostatic factors in those who remained healthy were lower compared
with those who developed disease.
|
Table 3 shows the relative risks of each
type of cardiovascular event for 1 unit (SD) increase
in the level of each hemostatic factor after first adjusting for age
and sex and then further adjusting for cardiovascular
risk factors and the presence of baseline IHD. There was no significant
association between factor VII or between vWF and the risk of any
cardiovascular or cerebrovascular event. Fibrinogen no
longer remained predictive of MI and angina when all risk factors were
taken into account, although the significant relationship of fibrinogen
with total events was maintained (P.05). TPA remained
significantly related to an increased risk of MI (P.05).
In contrast, the weak univariate association with MI became
statistically nonsignificant for fibrin D-dimer. This was probably a
reflection of stronger interactions between fibrin D-dimer and
preexisting disease and the conventional risk factors in subjects with
IHD than for subjects with stroke. Further analysis of those 55
subjects who died of MI revealed that the median levels of fibrinogen,
vWF, TPA, and D-dimer were all significantly higher compared with the
healthy group. The age- and sex-adjusted relative
risks were significant for each of the four factors, although on
multivariate analysis, none of the relative
risks reached statistical significance (data not shown).
|
Fibrinogen, TPA, and fibrin D-dimer levels were each significantly
related to the subsequent occurrence of stroke, although on
multivariate analysis, the magnitude of the
relative risk of fibrinogen with stroke increased slightly. This effect
may have been partly due to the inverse correlation between fibrinogen
levels and packyears, (r=-.22, P.01 (data not
shown). The figure shows that the age-
and sex-adjusted relative risks of stroke for each of the three
hemostatic factors were stronger than those of cigarette smoking and
LDL-cholesterol, whereas the association of
systolic blood pressure with stroke was slightly stronger than
that of fibrinogen. There was, however, considerable overlap between
the 95% confidence intervals of each factor.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The main finding in this study was that fibrinogen, TPA antigen, and fibrin D-dimer were strong predictors of stroke, independently of baseline IHD and conventional cardiovascular risk factors. These factors were also predictive of IHD (especially MI), although the relationships were weaker, and only TPA remained significantly related to MI on multivariate analyses.
These findings are consistent with other prospective studies relating fibrinogen to the incidence of stroke.3,5 However, the true strength of the association between fibrinogen and ischemic stroke may be greater than observed in this study because we were unable to reliably exclude patients with stroke of hemorrhagic origin from the stroke category. Fibrinogen has also been found to be an independent risk factor for transient ischemic attacks and minor ischemic strokes21 and in ischemic stroke survivors, fibrinogen predicted a second cardiovascular event within 2 years.22 The observation that fibrinogen levels were elevated in a small sample of patients who suffered a transient ischemic attack and did not subsequently rise suggests that fibrinogen may have a causal role in promoting cerebrovascular events.23 However, these findings have yet to be confirmed in other studies.
We also found that TPA antigen was strongly predictive of stroke as well as MI, independently of baseline IHD and established cardiovascular risk factors. To date, only one other prospective study has examined possible associations between TPA and risk of stroke,12 although the population was limited to a selected group of male physicians. In that study, exclusion of hemorrhagic events from multivariate analysis had no substantial effect on the magnitude of relative risk. Increases in TPA antigen levels in both the acute and chronic phases of ischemic stroke have been reported24 and TPA antigen has also been found to be a strong discriminator of subjects with and without a history of cerebrovascular events.25 These findings suggest that abnormal fibrinolytic activity may identify those at risk of cerebrovascular events.
A strong long-term association between high levels of TPA and the incidence of IHD has been reported in several studies.10,26 However, Ridker et al11 suggested that high TPA may represent a secondary response to the progression of atherosclerosis, because adjusting for atherosclerotic risk factors reduced the association between TPA and MI (but not stroke) to nonsignificance. The stronger relationship observed between TPA and stroke than for MI may reflect differences in risk factor associations between the two disease groups.
TPA antigen levels reflect inactive TPA/PAI complexes rather than free active TPA27,28 and thus raised levels may indicate elevated PAI activity and impaired fibrinolytic activity. TPA has recently been discovered to be mitogenic for smooth muscle cells, which suggests that overexpression may contribute to atherogenesis.29 Furthermore, plasmin, which is formed by the action of TPA on plasminogen, may also contribute to thrombogenesis through its ability to activate proteases, such as metalloproteases, which may weaken plaques and predispose them to rupture.30
We report for the first time that fibrin D-dimer was independently related to the risk of stroke. Data are sparse concerning the relationship between D-dimer and cerebrovascular disease. In one cross-sectional study, D-dimer was linked to the extent of atherosclerosis within the cerebral arteries.31 Takano et al32 showed that fibrin D-dimer levels were strongly associated with re-embolization after acute ischemic stroke. This implies that high fibrin turnover may contribute to a prothrombotic state, which may be critical for progression of disease within the cerebral arteries.
In the present study, D-dimer was a predictor of myocardial infarction on univariate, but not multivariate, analyses. This finding agrees with a case-control study,33 but not with two prospective studies, which observed D-dimer to be an independent predictor of IHD events.34,35 Fibrin D-dimer is an index of ongoing degradation of cross-linked fibrin, which may occur in response to thrombus formation. It may also be directly involved in atherogenesis.33 D-dimer is present in arterial lesions, stimulates smooth muscle cell proliferation, and is chemotactic for monocytes.36 It may also increase the synthesis of fibrinogen by stimulating the release of interleukin-6 from monocytes, which in turn stimulates fibrinogen synthesis in the liver.37
We could not confirm reports that factor VII is a predictor of IHD,1,6 nor did it appear to be a predictor of stroke. We also found that there was no independent relationship between vWF and risk of MI or stroke, in contrast with two studies which observed that vWF was independently related to incidence of IHD.35,38
In conclusion, our results indicate that hemostatic factors may have important etiologic roles in the development of cardiovascular and cerebrovascular events. In particular, measurement of both fibrinogen, TPA, and D-dimer levels may help to identify those at high risk of future stroke. Because our findings are based on a relatively low number of vascular events, further larger studies are needed to confirm these associations. If this occurs, controlled trials of reduction of fibrinogen and of oral anticoagulation, which lowers raised D-dimer levels,39 may be warranted in stroke and IHD prophylaxis.
|
Selected Abbreviations and Acronyms |
|---|
|
|
|
Acknowledgments |
|---|
We thank the British Heart Foundation for financial support.
Received February 21, 1997; accepted July 5, 1997.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533–537.[Medline] [Order article via Infotrieve]
2.
Yarnell JW, Baker IA, Sweetham PM, et al. Fibrinogen,
viscosity and white blood cell count are major risk factors for
ischemic heart disease. Circulation. 1991;83:836–844.
3. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501–505.[Abstract]
4. Stone MC, Thorp JM. Plasma fibrinogen: a major coronary risk factor. J R Coll Gen Pract. 1985;35:565–569.[Medline] [Order article via Infotrieve]
5.
Kannel WB, Wolf PA, Castelli WP, D'Agostino RB.
Fibrinogen and risk of cardiovascular disease: the
Framingham Study. JAMA. 1987;258:1183–1186.
6.
Heinrich J, Balleisen L, Schulte H, Assman G, Van de
Loo J. Fibrinogen and factor VII in the prediction of coronary
risk: results from the PROCAM study in healthy men. Arterioscler
Thromb. 1994;14:54–59.
7. Cremer P, Nagel D, Böttcher B, Seidel D. Fibrinogen: ein koronarer risikofactor. Diagn Labor. 1992;42:28–35.
8. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand. 1987;221:149–153.[Medline] [Order article via Infotrieve]
9.
Jansson JH, Nilsson TK, Olofsson BO. Tissue
plasminogen activator and other risk factors as
predictors of cardiovascular events in patients with
severe angina pectoris. Eur Heart J. 1991;12:157–161.
10.
Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de
Loo JCW for the European Concerted Action on Thrombosis, and
Disabilities Angina Pectoris Study Group. Hemostatic factors and the
risk of myocardial infarction or sudden death in patients with angina
pectoris. N Engl J Med. 1995;332:635–641.
11. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165–1168.[Medline] [Order article via Infotrieve]
12. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940–943.[Medline] [Order article via Infotrieve]
13.
Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE,
Housley E. Blood viscosity, fibrinogen, and activation of coagulation
and leukocytes in peripheral arterial disease,
and the normal population in the Edinburgh Artery Study.
Circulation. 1993;87:1915–1920.
14. Lowe GDO, Lee AJ, Rumley A, Price JF, Fowkes FGR. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96:168–173.[Medline] [Order article via Infotrieve]
15. Fowkes FGR, Housley E, Cawood EHH, MacIntyre CCA, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:382–392.
16. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings. Boston, Mass: John Wright PSG, Inc; 1982.
17. Lowe GDO, Wood DA, Douglas JT, et al. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost. 1991;65:339–343.[Medline] [Order article via Infotrieve]
18. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Org. 1962;27:645–658.[Medline] [Order article via Infotrieve]
19. Gillum RF, Fortmann SP, Prinease RJ, Korrke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 1984;108:150–158.[Medline] [Order article via Infotrieve]
20.
Leng GC, Lee AJ, Fowkes FGR, et al. Incidence, natural
history and cardiovascular events in
symptomatic and asymptomatic
peripheral arterial disease in the general
population. Int J Epidemiol. 1996;25:1172–1181.
21. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. B Med J. 1991;303:605–609.
22. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 1992;117:371–375.
23.
Ernst E, Matrai A, Marshall M. Blood rheology in
patients with transient ischaemic attacks. Stroke. 1988;19:634–636.
24.
Lindgren AL, Lindoff C, Norrving B, Åstedt B,
Johansson BB. Tissue plasminogen activator and
plasminogen activator inhibitor-1
in stroke patients. Stroke. 1996;27:1066–1071.
25.
Margaglione M, Di Minno G, Grandone E, et al.
Abnormally high circulation levels of tissue plasminogen
activator and plasminogen activator
inhibitor-1 in patients with a history of ischemic
stroke. Arterioscler Thromb. 1994;14:1741–1745.
26.
Jansson JH, Olofsson BO, Nilsson TK. Predictive value
of tissue plasminogen activator mass
concentration on long-term mortality in patients with coronary
heart disease. Circulation. 1993;88:2030–2034.
27. Nicoloso G, Hauert J, Kruithof EKO, van Melle G, Bachmann F. Fibrinolysis in normal subjects: comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost. 1988;59:299–303.[Medline] [Order article via Infotrieve]
28. Nilsson TK. Analysis of factors affecting tissue plasminogen activator activity and antigen concentrations before and after venous occlusion in 123 subjects. Clin Chem Enzymol Commun. 1989;1:335–341.
29.
Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada
SS, Barnathan ES. Plasminogen activator system
in human coronary atherosclerosis.
Arterioscler Thromb Vasc Biol. 1995;15:1432–1443.
30. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation. 1992;86(suppl III):III-95–III-99.
31. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assman G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374–379.[Medline] [Order article via Infotrieve]
32.
Takano K, Yamaguchi T, Uchida K. Markers of a
hypercoagulable state following acute ischemic stroke.
Stroke. 1992;23:194–198.
33.
Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma
concentrations of cross-linked fibrin degradation product (D-dimer)
and the risk of future myocardial infarction among apparently healthy
men. Circulation. 1994;90:2236–2240.
34. Fowkes FGR, Lowe GDO, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1992;342:84–86.
35. Lowe GDO, Rumley A, Yarnell JWG, Sweetnam PM, Thomas HF. Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator antigens are predictors of major ischaemic heart disease: the Caerphilly Study. Blood Coagul Fibrinolysis. 1995;6:156–157.
36.
Smith EB, Keen A, Grant A, Stirk C. Fate of fibrinogen
in human arterial intima. Arterioscler Thromb. 1990;10:263–275.
37.
Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of
fibrinogen synthesis by plasmin-derived fragments of fibrinogen and
fibrin: an indirect feedback pathway. Proc Natl Acad Sci
U S A.. 1982;79:1530–1534.
38. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol. 1994;88:601–604.[Medline] [Order article via Infotrieve]
39.
Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers
of thrombogenesis in chronic atrial fibrillation: effects of warfarin
therapy. Br Heart J. 1995;73:527–533.
This article has been cited by other articles:
 |
|
 |
|
  S.-Y. Chuang, C.-H. Bai, W.-H. Chen, L.-M. Lien, and W.-H. Pan Fibrinogen Independently Predicts the Development of Ischemic Stroke in a Taiwanese Population: CVDFACTS Study Stroke, May 1, 2009; 40(5): 1578 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Wirtz, L. S. Redwine, U. Ehlert, and R. von Kanel Independent Association Between Lower Level of Social Support and Higher Coagulation Activity Before and After Acute Psychosocial Stress Psychosom Med, January 1, 2009; 71(1): 30 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Frankel, J. B. Meigs, J. M. Massaro, P. W.F. Wilson, C. J. O'Donnell, R. B. D'Agostino, and G. H. Tofler Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease: The Framingham Offspring Study Circulation, December 9, 2008; 118(24): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Wirtz, L. S. Redwine, C. Baertschi, M. Spillmann, U. Ehlert, and R. von Kanel Coagulation Activity Before and After Acute Psychosocial Stress Increases With Age Psychosom Med, May 1, 2008; 70(4): 476 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Spiel, J. C. Gilbert, and B. Jilma Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes Circulation, March 18, 2008; 117(11): 1449 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Mausbach, R. von Kanel, K. Aschbacher, S. K. Roepke, J. E. Dimsdale, M. G. Ziegler, P. J. Mills, T. L. Patterson, S. Ancoli-Israel, and I. Grant Spousal Caregivers of Patients With Alzheimer's Disease Show Longitudinal Increases in Plasma Level of Tissue-Type Plasminogen Activator Antigen Psychosom Med, October 1, 2007; 69(8): 816 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tzoulaki, G. D. Murray, A. J. Lee, A. Rumley, G. D.O. Lowe, and F. G. R. Fowkes Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and Stroke: The Edinburgh Artery Study Circulation, April 24, 2007; 115(16): 2119 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Barac, U. Campia, and J. A. Panza Methods for Evaluating Endothelial Function in Humans Hypertension, April 1, 2007; 49(4): 748 - 760. [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. N. K. Chion, C. J. M. Doggen, J. T. B. Crawley, D. A. Lane, and F. R. Rosendaal ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men Blood, March 1, 2007; 109(5): 1998 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tzoulaki, G. D. Murray, A. J. Lee, A. Rumley, G. D.O. Lowe, and F. G. R. Fowkes Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study Eur. Heart J., February 1, 2007; 28(3): 354 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Campo, M. Valgimigli, P. Ferraresi, P. Malagutti, M. Baroni, C. Arcozzi, D. Gemmati, G. Percoco, G. Parrinello, R. Ferrari, et al. Tissue Factor and Coagulation Factor VII Levels During Acute Myocardial Infarction: Association With Genotype and Adverse Events Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2800 - 2806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K W Lee, A D Blann, K Jolly, G Y H Lip, and on behalf of the BRUM Investigators Plasma haemostatic markers, endothelial function and ambulatory blood pressure changes with home versus hospital cardiac rehabilitation: the Birmingham Rehabilitation Uptake Maximisation Study Heart, December 1, 2006; 92(12): 1732 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K H Costenbader and E W Karlson Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus, November 1, 2006; 15(11): 737 - 745. [Abstract] [PDF]
|
|
|
|
|
|
T. N. Bongers, M. P.M. de Maat, M.-L. P.J. van Goor, V. Bhagwanbali, H. H.D.M. van Vliet, E. B. Gomez Garcia, D. W.J. Dippel, and F. W.G. Leebeek High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke: Influence of ADAMTS13, Inflammation, and Genetic Variability Stroke, November 1, 2006; 37(11): 2672 - 2677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Al-Barjas, R. Ariens, P. Grant, and J. A. Scott Raised Plasma Fibrinogen Concentration in Patients With Abdominal Aortic Aneurysm Angiology, October 1, 2006; 57(5): 607 - 614. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Tzoulaki, G. D. Murray, J. F. Price, F. B. Smith, A. J. Lee, A. Rumley, G. D. O. Lowe, and F. G. R. Fowkes Hemostatic Factors, Inflammatory Markers, and Progressive Peripheral Atherosclerosis: The Edinburgh Artery Study Am. J. Epidemiol., February 15, 2006; 163(4): 334 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Smith, C. Patterson, J. Yarnell, A. Rumley, Y. Ben-Shlomo, and G. Lowe Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?: The Caerphilly Study Circulation, November 15, 2005; 112(20): 3080 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fibrinogen Studies Collaboration* Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality: An Individual Participant Meta-analysis JAMA, October 12, 2005; 294(14): 1799 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feinbloom and K. A. Bauer Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2043 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Woodward, G. D.O. Lowe, D. J. Campbell, S. Colman, A. Rumley, J. Chalmers, B. C. Neal, A. Patel, A. J. Jenkins, B. E. Kemp, et al. Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke Stroke, October 1, 2005; 36(10): 2143 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Rothwell, S. C. Howard, D. A. Power, S. A. Gutnikov, A. Algra, J. van Gijn, T. G. Clark, M. F.G. Murphy, C. P. Warlow, and for the Cerebrovascular Cohort Studies Collaborati Fibrinogen Concentration and Risk of Ischemic Stroke and Acute Coronary Events in 5113 Patients With Transient Ischemic Attack and Minor Ischemic Stroke Stroke, October 1, 2004; 35(10): 2300 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D.O. Lowe, A. Rumley, A. D. McMahon, I. Ford, D. St. J. O'Reilly, C. J. Packard, and for the West of Scotland Coronary Prevention Study Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1529 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ambrose and R. S. Barua The pathophysiology of cigarette smoking and cardiovascular disease: An update J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1731 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Johansson, J.-H. Jansson, B. Stegmayr, T. K. Nilsson, G. Hallmans, and K. Boman Hemostatic Factors as Risk Markers for Intracerebral Hemorrhage: A Prospective Incident Case-Referent Study Stroke, April 1, 2004; 35(4): 826 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, I. Juhan-Vague, et al. Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study Circulation, March 23, 2004; 109(11): 1343 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.D.O. Lowe, J. Danesh, S. Lewington, M. Walker, L. Lennon, A. Thomson, A. Rumley, and P.H. Whincup Tissue plasminogen activator antigen and coronary heart disease: Prospective study and meta-analysis Eur. Heart J., February 1, 2004; 25(3): 252 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Voetsch and J. Loscalzo Genetic Determinants of Arterial Thrombosis Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 216 - 229. [Abstract] [Full Text]
|
|
|
|
|
|
M. Roest and J. D. Banga Editorial Comment-- Genetic Make-Up for Increased PAI-1 Expression Protects Against Stroke Stroke, December 1, 2003; 34(12): 2828 - 2829. [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Lee and G. Y. H. Lip Effects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet Reactivity: A Systematic Review Arch Intern Med, October 27, 2003; 163(19): 2368 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Wakai, A Gleeson, and D Winter Role of fibrin D-dimer testing in emergency medicine Emerg. Med. J., July 1, 2003; 20(4): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.C. Kofoed, H.H. Wittrup, H. Sillesen, and B.G. Nordestgaard Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: The Copenhagen City Heart Study Eur. Heart J., March 2, 2003; 24(6): 567 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Naruszewicz, M.-L. Johansson, D. Zapolska-Downar, and H. Bukowska Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1249 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir Inflammation, Blood Pressure, and Stroke: An Opportunity to Target Primary Prevention? Stroke, December 1, 2002; 33(12): 2732 - 2733. [Full Text] [PDF]
|
|
|
|
|
|
H. Austin, M. I. Chimowitz, H. A. Hill, S. Chaturvedi, L. R. Wechsler, R. J. Wityk, E. Walz, J. L. Wilterdink, B. Coull, C. A. Sila, et al. Cryptogenic Stroke in Relation to Genetic Variation in Clotting Factors and Other Genetic Polymorphisms Among Young Men and Women * Editorial Comment Stroke, December 1, 2002; 33(12): 2762 - 2768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Stangl, G. Baumann, and K. Stangl Coronary atherogenic risk factors in women Eur. Heart J., November 2, 2002; 23(22): 1738 - 1752. [Full Text] [PDF]
|
|
|
|
|
|
P.H. Whincup, J. Danesh, M. Walker, L. Lennon, A. Thomson, P. Appleby, A. Rumley, and G.D.O. Lowe von Willebrand factor and coronary heart disease. Prospective study and meta-analysis Eur. Heart J., November 2, 2002; 23(22): 1764 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.D. Mills, M.W. Mansfield, and P.J. Grant Elevated fibrinogen in the healthy male relatives of patients with severe, premature coronary artery disease Eur. Heart J., August 2, 2002; 23(16): 1276 - 1281. [Abstract] [PDF]
|
|
|
|
|
|
A.L. Komarov, E.P. Panchenko, A.B. Dobrovolsky, Yu.A. Karpov, A.D. Deev, E.V. Titaeva, K.K. Davletov, A.R. Eshkeeva, and L.A. Markova D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease Eur. Heart J., August 2, 2002; 23(16): 1309 - 1316. [Abstract] [PDF]
|
|
|
|
|
|
J. D. Mills, M. W. Mansfield, and P. J. Grant Tissue Plasminogen Activator, Fibrin D-Dimer, and Insulin Resistance in the Relatives of Patients With Premature Coronary Artery Disease Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 704 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Braunstein, D. W. Kershner, P. Bray, G. Gerstenblith, S. P. Schulman, W. S. Post, and R. S. Blumenthal Interaction of Hemostatic Genetics With Hormone Therapy : New Insights To Explain Arterial Thrombosis in Postmenopausal Women Chest, March 1, 2002; 121(3): 906 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, D. Rothenbacher, A. Hoffmeister, M. Griesshammer, and H. Brenner Plasma Fibrin D-Dimer Levels and Risk of Stable Coronary Artery Disease: Results of a Large Case-Control Study Arterioscler Thromb Vasc Biol, October 1, 2001; 21(10): 1701 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Mukamal, P. P. Jadhav, R. B. D'Agostino, J. M. Massaro, M. A. Mittleman, I. Lipinska, P. A. Sutherland, T. Matheney, D. Levy, P. W.F. Wilson, et al. Alcohol Consumption and Hemostatic Factors: Analysis of the Framingham Offspring Cohort Circulation, September 18, 2001; 104(12): 1367 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Catto Genetic aspects of the hemostatic system in cerebrovascular disease Neurology, September 1, 2001; 57(90002): S24 - 30. [Abstract] [Full Text]
|
|
|
|
|
|
A. Sramek, J.H.C. Reiber, W.B.J. Gerrits, and F.R. Rosendaal Decreased Coagulability Has No Clinically Relevant Effect on Atherogenesis: Observations in Individuals With a Hereditary Bleeding Tendency Circulation, August 14, 2001; 104(7): 762 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bloomfield Rubins, J. Davenport, V. Babikian, L. M. Brass, D. Collins, L. Wexler, S. Wagner, V. Papademetriou, G. Rutan, and S. J. Robins Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol : The Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation, June 12, 2001; 103(23): 2828 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, A. Rumley, and G. D.O. Lowe Fibrin D-Dimer and Coronary Heart Disease : Prospective Study and Meta-Analysis Circulation, May 15, 2001; 103(19): 2323 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. O. Lowe, J. W. G. Yarnell, A. Rumley, D. Bainton, and P. M. Sweetnam C-Reactive Protein, Fibrin D-Dimer, and Incident Ischemic Heart Disease in the Speedwell Study : Are Inflammation and Fibrin Turnover Linked in Pathogenesis? Arterioscler Thromb Vasc Biol, April 1, 2001; 21(4): 603 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Folsom, N. Aleksic, E. Park, V. Salomaa, H. Juneja, and K. K. Wu Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease : The Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb Vasc Biol, April 1, 2001; 21(4): 611 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T C F Sykes, C Fegan, and D Mosquera Thrombophilia, polymorphisms, and vascular disease Mol. Pathol., December 1, 2000; 53(6): 300 - 306. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. Sechi, L. Zingaro, C. Catena, D. Casaccio, and S. De Marchi Relationship of Fibrinogen Levels and Hemostatic Abnormalities With Organ Damage in Hypertension Hypertension, December 1, 2000; 36(6): 978 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Girelli, C. Russo, P. Ferraresi, O. Olivieri, M. Pinotti, S. Friso, F. Manzato, A. Mazzucco, F. Bernardi, and R. Corrocher Polymorphisms in the Factor VII Gene and the Risk of Myocardial Infarction in Patients with Coronary Artery Disease N. Engl. J. Med., September 14, 2000; 343(11): 774 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hassan and H. S. Markus Genetics and ischaemic stroke Brain, September 1, 2000; 123(9): 1784 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Cote, C. Wolfson, S. Solymoss, A. Mackey, J. R Leclerc, D. Simard, F. Rouah, F. Bourque, and B. Leger Hemostatic Markers in Patients at Risk of Cerebral Ischemia Stroke, August 1, 2000; 31(8): 1856 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Korte and W. Riesen Latex-enhanced Immunoturbidimetry Allows D-Dimer Determination in Plasma and Serum Samples Clin. Chem., June 1, 2000; 46(6): 871 - 872. [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Killewich Intrinsic Fibrinolysis and Arterial Thrombosis Vascular and Endovascular Surgery, May 1, 2000; 34(3): 193 - 199. [PDF]
|
|
|
|
|
|
D. A. Lane and P. J. Grant Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease Blood, March 1, 2000; 95(5): 1517 - 1532. [Full Text] [PDF]
|
|
|
|
 |
|
 G J Prescott, R J Lee, G R Cohen, R A Elton, A J Lee, F G R Fowkes, and R M Agius Investigation of factors which might indicate susceptibility to particulate air pollution Occup. Environ. Med., January 1, 2000; 57(1): 53 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. G. Yarnell, P. M. Sweetnam, A. Rumley, and G. D. O. Lowe Lifestyle and Hemostatic Risk Factors for Ischemic Heart Disease : The Caerphilly Study Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Johansson, J.-H. Jansson, K. Boman, T. K. Nilsson, B. Stegmayr, and G. Hallmans Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex as Risk Factors for the Development of a First Stroke Stroke, January 1, 2000; 31(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W. M. van Hinsbergh, P. J. Kostense, J. J. Emeis, J. S. Yudkin, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D. A. Stehouwer von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects : The Hoorn Study Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 3071 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.H. Gershlick Blood markers of cardiovascular disease Eur. Heart J., October 2, 1999; 20(20): 1443 - 1444. [PDF]
|
|
|
|
|
|
A. J. Siegel, M. B. Sholar, J. H. Mendelson, S. E. Lukas, M. J. Kaufman, P. F. Renshaw, J. C. McDonald, K. B. Lewandrowski, F. S. Apple, J. J. Stec, et al. Cocaine-Induced Erythrocytosis and Increase in von Willebrand Factor: Evidence for Drug-Related Blood Doping and Prothrombotic Effects Arch Intern Med, September 13, 1999; 159(16): 1925 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Folsom, W. D. Rosamond, E. Shahar, L. S. Cooper, N. Aleksic, F. J. Nieto, M. L. Rasmussen, and K. K. Wu Prospective Study of Markers of Hemostatic Function With Risk of Ischemic Stroke Circulation, August 17, 1999; 100(7): 736 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mariani, J. Conard, F. Bernardi, R. Bertina, V. V. Garcia, H. Prydz, M. Samama, P. M. Sandset, M. Puopolo, M. V. Ciarla, et al. Oral Contraceptives Highlight the Genotype-Specific Association Between Serum Phospholipids and Activated Factor VII Arterioscler Thromb Vasc Biol, August 1, 1999; 19(8): 2024 - 2028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. van 't Hooft, A. Silveira, P. Tornvall, A. Iliadou, E. Ehrenborg, P. Eriksson, and A. Hamsten Two Common Functional Polymorphisms in the Promoter Region of the Coagulation Factor VII Gene Determining Plasma Factor VII Activity and Mass Concentration Blood, May 15, 1999; 93(10): 3432 - 3441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ebrahim, O. Papacosta, P. Whincup, G. Wannamethee, M. Walker, A. N. Nicolaides, S. Dhanjil, M. Griffin, G. Belcaro, A. Rumley, et al. Carotid Plaque, Intima Media Thickness, Cardiovascular Risk Factors, and Prevalent Cardiovascular Disease in Men and Women : The British Regional Heart Study Stroke, April 1, 1999; 30(4): 841 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lee, P. I. Mowbray, G. D.O. Lowe, A. Rumley, F. G. R. Fowkes, and P. L. Allan Blood Viscosity and Elevated Carotid Intima-Media Thickness in Men and Women : The Edinburgh Artery Study Circulation, April 21, 1998; 97(15): 1467 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Mills, M. W. Mansfield, and P. J. Grant Tissue Plasminogen Activator, Fibrin D-Dimer, and Insulin Resistance in the Relatives of Patients With Premature Coronary Artery Disease Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 704 - 709. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||